PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.

NCT03283943 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer
Primary Peritoneal Carcinoma
Fallopian Tube Cancer

Interventions

RADIATION: Focal radiotherapy
DRUG: Durvalumab

Sponsor

British Columbia Cancer Agency

Collaborators

[object Object]